Pfizer Inc. has acquired California-based NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialisation of products for the treatment of attention deficit hyperactivity disorder (ADHD).
Upon the closing of the transaction, Pfizer now holds exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the US for the treatment of ADHD. Quillivant XR received approval from the US Food and Drug Administration (FDA) on September 27, 2012, and is expected to be available in pharmacies in the US in January 2013.
Quillivant XR is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Quillivant XR in a safe place to prevent misuse and abuse. Selling or giving away Quillivant XR may harm others and is against the law.
Quillivant XR is a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD. It may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.